# Botulinum Toxin Type A

## Botox 100 Unit/Vial

| 藥物代碼 | IBOT |
| :--- | :--- |
| 適應症 | For the treatment of strabismus & blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients &gt;= 12 years. Treatment of spasmodic torticollis \(cervical dystonia\) in adults. Treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients &gt;= 2 years. Treatment of primary hyperhidrosis of the axilla. Treatment of glabellar lines associated with corrugator &/or procerus muscle activity. Management of focal spasticity, including treatment of upper limb spasticity associated with stroke in adults. |
| 副作用 | Localized pain, tenderness &/or bruising, local weakness, ptosis, vertical deviation, irritation/tearing. Rarely, skin rash \(including erythema multiforme, urticaria & psoriasiform eruption\), pruritus, allergic reactions, dysphagia, pneumonia.Dermatologic: Injection site reaction \(cervical dystonia, 5% to 22%; glabellar lines, 3% \)Gastrointestinal: Xerostomia \(cervical dystonia, 13% to 39% \)Musculoskeletal: Muscle weakness \(cervical dystonia, 11% to 56% \)Neurologic: Difficulty speaking \(cervical dystonia, 6% to 28% \), Headache \(9% to 11% \)Ophthalmic: Disorder of eye \(cervical dystonia, 6% to 17% \)Respiratory: Nasopharyngitis \(glabellar lines, 10% \) |
| 禁忌 | Myasthenia gravis or Eaton Lambert syndrome, infection at inj site. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | Cervical dystonic \(spasmodic torticollis\) Individualised dosing. Strabismus For vertical muscles & for horizontal strabismus of &lt; 20 prism diopters: 1.25-2.5 u in any 1 muscle. For horizontal strabismus of 20-50 prism diopters: 2.5-5 u in any 1 muscle. For persistent VI nerve palsy of &gt;= 1 month: 1.25-2.5 u in the medial rectus muscle. Max: 25 u as single inj for any 1 muscle. Blepharospasm Initially 1.25-2.5 u injected into the medial & lateral pre-tarsal orbicularis oculi of the upper lid & into the lateral pre-tarsal orbicularis oculi of the lower lid. Max cumulative dose: 200 u/2 months. VII nerve disorders Patients with hemifacial spasm or VII nerve disorder should be treated as for unilateral blepharospasm. Max cumulative dose: &lt;=200 u/2 months. Spasticity \(due to juvenile cerebral palsy\) 4 u/kg into each of 2 sites in the medial & lateral heads of the gastrocnemius muscle of the affected lower limb\(s\). Primary hyperhidrosis of the axillae 50 u intradermally to each axilla evenly distributed in multiple sites about 1-2 cm apart. Treatment may be repeated every 2 months or more. Glabellar lines 4 u into each of 5 sites, 2 in each corrugator muscle & 1 in the procerus muscle for a total dose of 20 u. Focal spasticity associated with stroke Max 360 u divided among selected muscles \(typically the flexor muscles of the elbow, wrist & fingers\) at any treatment session. Reinject at 12-16 weeks intervals. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM, SC |
| 乾粉稀釋液 | 加入0.9% N/S 10mL稀釋後.每0.1 mL含有1 Unit |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Dysport 500 Unit/Vial

| 藥物代碼 | IDYS |
| :--- | :--- |
| 適應症 | NA |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | N/A |
| 用法用量 | Blepharospasm 1.25 ~ 2.5 u into the medial & lateral orbicularis oculi of the upper lid & into lateral orbicularis oculi of he lower lid. Max 100 u every 12 weeks. Hemifacial spasm, spasmodic torticolis Individulised dosage. Paediatric cerebral palsy Administer into each of 2 sites in the medial and lateral heads of the affected gastrocnemius muscle. In hemiplegia : total dose of 4 u / kg body wt in the affected limb. In diplegia : total dose of 6 u / kg body wt divided beween the affected lims. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

